Mammastatin replacement therapy

Drug Profile

Mammastatin replacement therapy

Latest Information Update: 04 Jan 2007

Price : $50

At a glance

  • Originator University of Michigan
  • Developer Biotherapies; M. D. Anderson Cancer Center
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 19 May 2000 A phase I trial has been temporarily suspended while production control issues are addressed
  • 09 Feb 2000 Data have been added to the therapeutic trials and pharmacodynamics sections
  • 30 Jun 1999 Phase-I clinical trials for Breast cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top